Asset Management January 2023

For professional investors only.



CS (Lux) Digital Health Equity Fund A **FUR**



Fund information Equity				
2'276'585'313 Fund total net assets in USD				
Share class TNA, EUR 28'800'183	Share class NAV, EUR 120.33	Management fee p.a. ¹ 1.60%		
MTD (net) return 8.68%	QTD (net) return 8.68%	YTD (net) return 8.68%		

Fund details	
Investment Manager	Thomas Amrein, Fang Liu
Fund launch date	14.12.2017
Share class launch date	14.09.2018
Share class	Α
Share class currency	EUR
Distribution policy	Distributing
Fund domicile	Luxembourg
ISIN	LU1877633989
Benchmark	No benchmark


Investment Policy


Health care cost to society has risen to levels which are no longer sustainable. This fund invests globally in innovative companies which are driving a revolution in the health care sector through the application of technology. It offers diversified exposure to the digital health universe, which is one of the fastest growing segments in the health care industry. The investment universe comprises three segments: Research & Development, Treatments and Efficiency. The fund invests in "pure-play" digital health companies, which are typically small to mid-sized. The investment objective is long-term capital appreciation from actively managed exposure to this secular growth theme.



Portfolio net - cumulated return

Past performance does not predict future returns. Neither simulated nor historical performance is a reliable indicator for current or future performance.





Performance overview - monthly & YTD

since 01.01.2023, in %

,	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
Portfolio net	8 68												8 68

Performance overview - yearly

since 01.10.2018, in %						
	2018	2019	2020	2021	2022	2023
Portfolio net	-20.01	35.62	71.16	-13.69	-32.12	8.68

¹ If the currency of a financial product and/or its costs is different from your reference currency, the return and cost may increase or decrease as a result of currency fluctuations. ESG stands for environmental (E), social (S), and governance (G).

Performance overview

since 01.10.2018, in %

Rolling Returns					Annualized	Returns
	1 months	3 months	1 year	3 years	5 years	ITD
Portfolio net	8.68	-2.70	-12.36	2.19	n/a	3.94

Risk overview - ex post

since 01.10.2018, in %

			Annualize	d risk, in %
	1 year	3 years	5 years	ITD
Portfolio volatility	30.25	28.23	n/a	26.97

Potential Risks


The Fund's risk and reward profile does not reflect the risk inherent in future circumstances that differ from what the Fund has experienced in the recent past. This includes the following events which are rare but can have a large impact.

- Credit risk: Issuers of assets held by the Fund may not pay income or repay capital when due. The Fund's investments have low credit risk.
- Liquidity risk: Assets cannot necessarily be sold at limited cost in an adequately short timeframe. The Fund's investments may be
- prone to limited liquidity. The Fund will endeavor to mitigate this risk by various measures. Counterparty risk: Bankruptcy or insolvency of the Fund's derivative counterparties may lead to payment or delivery default.
- Operational risk: Deficient processes, technical failures or catastrophic events may cause losses.
- Political and Legal risks: Investments are exposed to changes of rules and standards applied by a specific country. This includes restrictions on currency convertibility, the imposing of taxes or controls on transactions, the limitations of property rights or other
- Sustainability risks: Sustainability risks are environmental, social or governance events or conditions that can have a material


negative effect on the return, depending on the relevant sector, industry and company exposure.

The product's investment objectives, risks, charges and expenses, as well as more complete information about the product, are provided in the prospectus (or relevant offering document), which should be read carefully before investing.


The full offering documentation including complete information on risks may be obtained free of charge from a Credit Suisse client advisor, representative, or, where applicable, via Fundsearch (credit-suisse.com/fundsearch) The investment promoted in this marketing material concerns the acquisition of units or shares in a fund and not of any underlying assets. The underlying assets are owned by the fund only.



Asset breakdown by Subtheme



Asset breakdown by risk currency



Asset breakdown by risk country

	in %	Portfolio Portfolio
United States	73.57	
China	5.65	
Japan	5.35	
Jersey, Channel Islands	2.89	I
Canada	2.86	
Denmark	2.73	
Switzerland	2.22	
Germany	2.16	
Netherlands	1.49	
Others	1.08	

Key figures

	Portfolio
Number of securities	64

Fund Statistics - ex post

	1 year	3 years
	Portfolio	Portfolio
Maximum drawdown, in %	-21.59	-47.10

² The actual risk can vary significantly if you redeem at an early stage and you may get back less. The Summary Risk Indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets. Be aware of currency risk if your reference currency differs from the currency of the Product. You may receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. Investors shall note that the Product may be exposed to further risks such as operational, counterparty, political, sustainability and legal risks that are not included in the Summary Risk Indicator. This Product does not include any protection from future market performance so you could lose some or all of your investment.

Largest contributors and detractors

MTD as of 31.01.2023

			Portfolio	
Contributors	Total return	Weight	Total effect	Detrators
ZAI LABORATORY ADR	37.60%	3.40%	1.41%	JD HEAL
REPRESENTING LT				ARROWH
EXACT SCIENCES CORP	36.25%	3.41%	1.16%	PHARMA
10X GENOMICS INC CLASS A	28.61%	3.50%	0.96%	FATE TH
ALIGN TECHNOLOGY INC	27.82%	3.10%	0.81%	SHOCKW
NOVOCURE LTD	24 59%	3.00%	0.72%	INARI ME

Detrators	Total return	Weight	Portfolio Total effect
JD HEALTH INTERNATIONAL INC	-9.57%	2.81%	-0.30%
ARROWHEAD PHARMACEUTICALS INC	-13.73%	1.77%	-0.29%
FATE THERAPEUTICS INC	-58.33%	0.08%	-0.25%
SHOCKWAVE MEDICAL INC	-8.03%	2.87%	-0.21%
INARI MEDICAL INC	-10.27%	1.71%	-0.19%

Performance commentary

The fund outperformed the benchmark in January. Among the top performance contributors were Zai Lab, Exact Sciences, and 10x Genomics. Zai Lab benefited from the positive sentiment toward Chinese stocks following the reopening. Exact Sciences was up more than 30% thanks to a competitive colon cancer test being considered as less of a threat, and good Q4 earnings driven by strong Cologuard volume. 10x Genomics recovered rapidly after management noted Q4 results exceeded internal expectations and reported strong demand for its new product at a flagship healthcare conference. Detractors were JD Health, Arrowhead Pharmaceuticals, and Fate Therapeutics. JD Health gave back some returns after the COVID-19 pandemic rapidly abated in China. Arrowhead plunged after data on their liver disease drug did not match some expectations. Fate fell after it announced that it will end the Janssen Biotech partnership, and elected to develop a second-generation product suite.

Market comments

Equity markets advanced in January, mostly driven by the peak inflation narrative in the US and Europe, as well as a renewed positive sentiment about the global economy (source: IMF). Although the US is seeing a flurry of tech layoffs, softer discretionary spending trends, and a soft start to the earnings season, the market seems to be increasingly discounting a soft-landing scenario of the US economy. In addition, Chinese equities saw a reopening rally as the zero-COVID-19 policy was abruptly ended.

Comments on transactions

Against a still volatile market backdrop, we are very selectively working on positions, trying not to create unnecessary churn. We took some profit in stronger performers, such as Zai Lab, JD Health, Medley, HealthEquity, etc. We added back to Shockwave and Illumina.

This commentary is intended only to describe past performance of the investment strategy. The strategy invests in individual securities which are owned in the strategy as part of a carefully constructed and diversified portfolio. The information presented in this commentary may be based on the assessment of CS' portfolio managers. Market developments described in this document are subject to a number of risks and uncertainties and are neither reliable indicators nor a guarantee of future results/performance. The information in this commentary may change after the date of issuance of this document without notice and should not be construed as a recommendation to buy or sell individual securities named herein.

Key identifiers

Instrument Name	Credit Suisse (Lux) Digital Health Equity Fund A
ISIN	EUR LU1877633989
Bloomberg ticker	CSGDHAE LX
Valor no.	43558975
Benchmark	No benchmark

Key facts

Fund management company	Credit Suisse Fund Management S.A.
UCITS	Yes
SFDR Classification	Article 8
Accounting year end	31. May
Securities lending	Yes
Ongoing charges ³	1.83%
Subscription notice period	daily
Subscription Settlement Period	T + 2
Redemption notice period	daily
Redemption Settlement Period	T + 2
Distribution frequency	annually
Distribution currency	EUR
Cut-off time	15:00 CET
Swinging single pricing (SSP*)	partial swing NAV

ESG Approach

This fund promotes environmental, social and governance (ESG) characteristics (within the meaning of Art. 8 of Regulation (EU) 2019/2088). It applies the CSAM Sustainable Investing Policy (www.credit-suisse.com/esg), including norms-based, values-based and business conduct exclusions, to combine ESG factors with traditional financial analysis to make an ESG adjusted risk-return assessment, which serves as the basis for the portfolio construction. For further information about the ESG investment criteria and the sustainability-related aspects of the fund please consider the legal and regulatory documents of the fund (such as, e.g., the prospectus) and visit www.credit-suisse.com/esg. In addition to sustainability-related aspects, the decision to invest in the fund should take into account all objectives and characteristics of the fund as described in its prospectus, or in the information which is to be disclosed to investors in accordance with applicable regulations.

Certain data points disclosed in this factsheet are provided for mere transparency purposes and are not linked to a specific ESG investment process, nor to CSAM ESG methodology. For details about the fund's ESG decision-making process, please refer to the fund's prospectus.

ESG Characteristics

Sustainable Investment Objective	Active Ownership	ESG Integration	Exclusion Criteria	ESG Benchmark
	$ \overline{\mathcal{L}} $	$ \overline{\mathcal{L}} $	$ oldsymbol{ oldsymbol{Z}} oldsymbol{ oldsymbol{Z}} oldsymbol{ oldsymbol{S}} oldsymbol{ oldsymbol{S}} oldsymbol{Oldsymbol{S}} oldsymbol{Oldsymbol{S}}$	

³ If the currency of a financial product and/or its costs is different from your reference currency, the return and cost may increase or decrease as a result of currency fluctuations.

ESG Overview

According to MSCI ESG methodology

	Portfolio
ESG Rating	BBB
ESG Quality score	5.10
Environmental score	6.18
Social score	4.44
Governance score	5.77
Coverage for Rating/Scoring	95.81%
Weighted Average Carbon Intensity (Tons of CO2e/\$M sales)	21.66
Coverage for Carbon Intensity	96.70%

Note: The total carbon intensity figure shown in this section may be higher than the total in the breakdown graph. This is because the figure is normalized, and actual weights are inflated because of limited data coverage. For further information on the MSCI methodology for the above listed ESG data points, please refer to the glossary.

Top 10 positions - ESG Characteristics

In terms of the fund's total economic exposure. Certain data points disclosed in this table are provided for mere transparency purposes and are not linked to a specific ESG investment process, nor to CSAM ESG methodology. For details about the fund's ESG decision-making process, please refer to the fund's prospectus. Source: MSCI

Instrument Name	Weight in portfolio	GICS sector	MSCI ESG Rating	Controversy flag (Carbon intensity tCO2e / \$M sales)
SHOCKWAVE MEDICAL INC	3.56%	Health Care	А	Green	17.30
VEEVA SYSTEMS INC CLASS A	3.46%	Health Care	А	Green	7.10
ALIGN TECHNOLOGY INC	3.33%	Health Care	А	Green	20.10
EXACT SCIENCES CORP	3.30%	Health Care	А	Yellow	48.10
10X GENOMICS INC CLASS A	3.30%	Health Care	BB	Green	13.60
EVOLENT HEALTH INC CLASS A	3.12%	Health Care	В	Green	6.40
ZAI LABORATORY ADR REPRESENTING LT	3.10%	Health Care	BBB	Green	104.50
DEXCOM INC	3.07%	Health Care	А	Green	17.60
PHREESIA INC	3.06%	Health Care	BB	Green	7.10
INSPIRE MEDICAL SYSTEMS INC	3.01%	Health Care	BBB	Green	17.30

Note: For further information on the methodology for the above listed ESG data points, please refer to the glossary.

Asset breakdown by ESG rating



Note: For further information on MSCI's ESG rating methodology and the difference between categories "not ratable" and "no data coverage", please refer to the glossary.

Carbon emission intensity contribution by GICS sector

Tons of CO2 equivalent emission intensity (GHG scopes 1 & 2) per \$m sales, weighted by portfolio exposure to sectors according to the GICS sector split. Source: MSCI

	Portfolio	Portfolio
Health Care	20.02	
Consumer Discretionary	0.88	
Consumer Staples	0.04	
Cash	0.00	
Others	0.00	
Total	20.94	

Note: Security weighted data coverage is 96.70% for the portfolio. The total shown in this section may be lower than the one in the 'ESG Overview' section. This is because the figures in this breakdown are not normalized and use the actual weights. For further information on the Carbon emission intensity, please refer to the glossary.

Asset breakdown by ESG controversy flag

In % of fund total economic exposure to investee companies. Source: MSCI

	in %	Portfolio Portfolio
Green	90.17	
Yellow	5.86	
Orange	0.54	
Red	-	
No data coverage	3.41	

Note: Exposure to investee companies represents 99.97% of portfolio weight for this share class. MSCI only provides data on ESG controversies for corporate issuers. Any remaining instruments (e.g., government bonds) are excluded from this breakdown. For further information on MSCI's ESG controversy flag methodology, please refer to the glossary.

Glossary

Annualized Risk	Annualized risk is a statistic, which is used to measure the risk of a fund by describing the range of returns, which were achieved in the observation period are most likely to be achieved. Greater volatility implies greater risk.
Carbon emission intensity	The weighted average emissions intensity, which is provided by MSCI ESG, divides the Scopes 1 & 2 emissions in tons of CO2-equivalent by million \$ sales. Intensities are broken down by GICS sector and are security weighted.
ESG benchmark	A ticked 'ESG benchmark' box reflects that the ESG section in this document compares the ESG performance of the portfolio with an ESG index. In case the box is not ticked, this means that the ESG section in this document compares the ESG performance of the portfolio with a non-ESG index. The investor shall read the legal documentation of the Fund to understand how the benchmark is used. In any case, a ticked 'ESG benchmark' box does not mean that the ESG benchmark is used to attain the ESG strategy of the fund.
ESG Controversy Flag	ESG Controversy Flag is designed to provide timely and consistent assessments of ESG controversies involving publicly traded companies and fixed income issuers. A controversy case is typically a one-off event such as an environmental oil spill, an accident, or allegations such as safety issues in a production facility. Controversy flags can be red, orange, yellow or green. Red indicates that a company is involved in one or more very severe controversies. Orange indicates that a company has been involved in one or more recent severe structural controversies that are ongoing. Yellow indicates that the company is involved in severe-to-moderate level controversies. Green indicates that the company is not involved in any major controversies. For further information on the methodology, please refer to www.msci.com/our-solutions/esg-investing/.
ESG Quality score	The ESG Quality score, based on MSCI ESG scores of underlyings, is measured on a scale from 0 (very poor) to 10 (very good). It does not correspond directly to the underlying Environment, Social and Governance Pillar scores. The Pillar scores are derived on an absolute basis, while the portfolio ESG Quality score is adjusted by MSCI ESG to reflect the industry-specific level of ESG risk exposure. According to the MSCI methodology, additional adjustments are made based on the positive (upward) and negative (downward) ESG trends (or ESG rating momentum), as well as portfolio exposure to ESG laggards. As Pillar scores are absolute, and the portfolio ESG Quality score is relative, the first cannot be averaged to derive the latter. The coverage rate is security weighted.
Issuer ESG Rating	Company and Government ESG Ratings, which are provided by MSCI ESG, are measured on a scale from AAA (highest rating) to CCC (lowest rating). Company ESG Ratings are based on the issuer's exposure to industry specific ESG risks and its ability to mitigate those risks relative to peers. Company ESG Ratings are calculated on an industry relative basis while the underlying individual E, S and G Ratings are absolute. Hence, the ESG Rating cannot be seen as an average of the individual E, S and G Ratings. Government ESG Ratings identify a country's exposure to and management of ESG risk factors and explain how these factors might impact the long-term sustainability of its economy. They are derived from 0-10 scores on underlying factors in the E, S and G pillars. For further information on the MSCI methodology, please refer to www.msci.com/our-solutions/esg-investing/.
GICS	Global Industry Classification Standard
ITD	Inception-to-date
LuxFLAG ESG	For more information about the methodology and label validity, please visit luxflag.org. Validity: 01 January 2023 - 31 December 2023
MSCI ESG Methodology	For further information on the methodology applied to assess the ESG characteristics of the investments, please refer to www.msci.com/our-solutions/esg-investing/
Not ratable / No data coverage	Where MSCI considers an asset type for ESG analysis but data on an economic exposure is unavailable due to a lack of data from the data vendor, the investment falls under the category "No data coverage". Where MSCI considers an asset type out of scope for ESG analysis (e.g. Cash, Currency), the economic exposure falls under the category "Not ratable". For further information regarding excluded asset types, please refer to www.msci.com/our-solutions/esg-investing.
Ongoing Charges	The calculation of the ongoing charge is based on the Committee of European Securities Regulators/10-674 Directive. For a maximum of 12 months from December 31, 2020, the ongoing charges figure is based on estimated expenses. From December 2021, the ongoing charges figure is based on last year's expenses for the year ending December 2021. It excludes performance fees and portfolio transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling shares/units in another collective investment undertaking
Portfolio ESG Rating	Discrepancies may exist between the portfolio-level ESG Rating calculated by CSAM applying the MSCI methodology (provided in this factsheet) and the ESG Ratings displayed by other providers (e.g., MSCI ESG fund ratings). There are two main reasons for these potential deviations: (1) CSAM uses updated month-end holdings data as basis for its calculation, and (2) CSAM uses the underlying security data (e.g., exposures to target funds or to convertible bonds), thus applying a look-through approach where possible. The coverage rate is security weighted. For further information on the MSCI methodology, please refer to www.msci.com/our-solutions/esg-investing/.
Sustainable investment objective	Where the 'sustainable investment objective' box is ticked, this means that the product implements CSAM investment strategies that allocate capital into companies that offer solutions to society's challenges and meet a sustainable investment objective. The sustainable investment objective is achieved through a dedicated investment process focusing on investments in themes and sectors whose economic activities address specific ESG challenges. An unticked box reflects that the product does not aim to meet a sustainable investment objective.
Sustainable thematic	This product undertakes investments that are dedicated to addressing the United Nations Sustainable Development Goals (e.g. education or clean energy) through a thematic approach.

Warning statements

Swinging Single Pricing	For more details, please refer to the relevant chapter "Net Asset Value" of the fund's prospectus
Performance start date	Performance calculation and presentation start with the first full month of an invested strategy. This can lead to a difference in launch and performance start dates.
PRIIP SRI	The Summary Risk Indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets.

ESG Notes

The figures contained in this section are not audited. Where ESG related information, statements and scorings are made in this document, CS may have, partially or entirely, relied on publicly available information, internally developed data and/or information obtained from other third-party sources which CS believes to be reliable. CS' ability to verify such ESG objectives may be limited by the reliability of the data available in respect of the underlying assets and the status of the regulations in relation to tracking and providing such data. CS has not independently verified any information obtained from these public and third-party sources and cannot make any representations or warranties as to its accuracy, completeness or reliability. It is possible that the data from ESG data providers may be incorrect, unavailable, or not fully updated. This is especially true where CS has limited access to data from external parties regarding the underlying elements of an investment, for example due to a lack of look-through data. Such data gaps could result in an incorrect assessment of a sustainability practice and/or related sustainability risks and opportunities. Investors shall not use the ESG data provided in this document for the sake of meeting their own regulatory disclosure or reporting requirements. CS cannot make any guarantee about the content or completeness of such ESG disclosures, which remain subject to change and cannot be relied upon. In particular, CS shall not be liable for any errors or omissions in connection with any ESG data herein, or for any direct, indirect, special, punitive, consequential or any other damages (including lost profits). In the absence of a standardized, industry-wide ESG classification system, CS has developed its own ESG framework (the "CS Sustainable Investment Framework"). Therefore, investors should note that the ESG classification of the fund reflects CS' opinion and is based on the CS Sustainable Investment Framework which classification may vary from the classificatio



Want to learn more?

Visit: https://credit-suisse.com/fundsearch

Important information

Source: Credit Suisse, unless otherwise specified

This material constitutes marketing material of Credit Suisse Group AG and/or its affiliates (hereafter "CS").

This material does not constitute or form part of an offer or invitation to issue or sell, or of a solicitation of an offer to subscribe or buy, any securities or other financial instruments, or enter into any other financial transaction, nor does it constitute an inducement or incitement to participate in any product, offering or investment.

This marketing material is not a contractually binding document or an information document required by any legislative provision.

Nothing in this material constitutes investment research or investment advice and may not be relied upon. It is not tailored to your individual circumstances, or otherwise constitutes a personal recommendation, and is not sufficient to take an investment decision.

The information and views expressed herein are those of CS at the time of writing and are subject to change at any time without notice. They are derived from sources believed to be reliable. CS provides no guarantee with regard to the content and completeness of the information and where legally possible does not accept any liability for losses that might arise from making use of the information. If nothing is indicated to the contrary, all figures are unaudited. The information provided herein is for the exclusive use of the recipient.

The information provided in this material may change after the date of this material without notice and CS has no obligation to update the information

This material may contain information that is licensed and/or protected under intellectual property rights of the licensors and property right holders. Nothing in this material shall be construed to

impose any liability on the licensors or property right holders. Unauthorised copying of the information of the licensors or property right holders is strictly prohibited.

The full offering documentation including, the prospectus or offering memorandum, the Key Investor Information Document (KIID), the Key Information Document (KID), the fund rules, as well as the annual and bi-annual reports ("Full offering documentation"), as the case may be, may be obtained free of charge in one of the languages listed below from the legal entity/entities indicated below and where available via FundSearch (credit-suisse.com/fundsearch).

Information on your local distributors, representatives, information agent, paying agent, if any, and your local contacts in respect of the investment product(s) can be found below.

The only legally binding terms of any investment product described in this material, including risk considerations, objectives, charges and expenses are set forth in the prospectus, offering memorandum, subscription documents, fund contract and/or any other fund governing documents.

For a full description of the features of the products mentioned in this material as well as a full description of the opportunities, risks, and costs associated with the respective products, please refer to the relevant underlying securities prospectuses, sales prospectuses, or other additional product documents, which we will be pleased to provide to you at any time upon request.

The investment promoted in this marketing material concerns the acquisition of units or shares in a fund and not of any underlying assets. The underlying assets are owned by the fund only. This material may not be forwarded or distributed to any other person and may not be reproduced. Any forwarding, distribution or reproduction is unauthorized and may result in a violation of the U.S. Securities Act of 1933, as amended (the "Securities Act,"). The securities referred to herein have not been, and will not be, registered under the Securities Act, or the securities laws of any

states of the United States and, subject to certain exceptions, the securities may not be offered, pledged, sold or otherwise transferred within the United States or to, or for the benefit or account

In addition, there may be conflicts of interest with regard to the investment.

In connection with the provision of services, Credit Suisse AG and/or its affiliates may pay third parties or receive from third parties, as part of their fee or otherwise, a one-time or recurring fee (e.g., issuing commissions, placement commissions or trailer fees).

Prospective investors should independently and carefully assess (with their tax, legal and financial advisers) the specific risks described in available materials, and applicable legal, regulatory, credit, tax and accounting consequences prior to making any investment decision.

The alternative investment fund manager or the (UCITS) management company, as applicable, may decide to terminate local arrangements for the marketing of the shares/units of a fund, including terminating registrations or notifications with the local supervisory authority.

A summary of investor rights for investing into European Economic Area domiciled investment funds managed or sponsored by Credit Suisse Asset Management can be obtained in English via www.credit-suisse.com/am/regulatory-information, local laws relating to investor rights may apply.

Regulator / Supervisor legal entity: Comisión Nacional del Mercado de Valores ("CNMV"), Edison, 4, 28006 Madrid Spain, Tel: 34 91 585 15 00, Website: www.cnmv.es Distributor: Credit Suisse AG, Sucursal en España*, Calle Ayala 42, 28001 Madrid, España

Legal entity, from which the full offering documentation, the key investor information document (KIID), the fund rules, as well as the annual and bi-annual reports, if any, may be obtained free of

Language versions available: English, German, French or Italian